MedPath

Oppilan Pharma Ltd.

Oppilan Pharma Ltd. logo
🇬🇧United Kingdom
Ownership
Subsidiary
Established
2015-01-01
Employees
1
Market Cap
-
Website
https://oppilan.com

Clinical Trials

4

Active:3
Completed:1

Trial Phases

2 Phases

Phase 1:3
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (75.0%)
Phase 2
1 (25.0%)

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Phase 2
Active, not recruiting
Conditions
Colitis, Ulcerative
Interventions
Drug: Placebo
First Posted Date
2021-12-14
Last Posted Date
2024-11-13
Lead Sponsor
Oppilan Pharma Ltd
Target Recruit Count
213
Registration Number
NCT05156125
Locations
🇺🇸

Local Site # 840030, Garden Grove, California, United States

🇺🇸

Local Site # 840026, Lancaster, California, United States

🇺🇸

Local Site # 840040, San Diego, California, United States

and more 74 locations

A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2020-06-30
Last Posted Date
2021-05-28
Lead Sponsor
Oppilan Pharma Ltd
Target Recruit Count
12
Registration Number
NCT04451811
Locations
🇬🇧

Celerion, Belfast, Northern Ireland, United Kingdom

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.